MNKD icon

MannKind Corp

5.63 USD
-0.02
0.35%
At close Feb 7, 4:00 PM EST
After hours
5.69
+0.06
1.07%
1 day
-0.35%
5 days
0.36%
1 month
-10.06%
3 months
-23.82%
6 months
12.38%
Year to date
-14.70%
1 year
64.14%
5 years
288.28%
10 years
-85.01%
 

About: MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Employees: 414

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

135% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 17

60% more call options, than puts

Call options by funds: $17M | Put options by funds: $10.6M

52% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 52

33% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 4 (+1) [Q3]

33% more capital invested

Capital invested by funds: $731M [Q2] → $971M (+$240M) [Q3]

10% more funds holding

Funds holding: 208 [Q2] → 229 (+21) [Q3]

4.8% more ownership

Funds ownership: 51.38% [Q2] → 56.17% (+4.8%) [Q3]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$9
60%
upside
Avg. target
$9.50
69%
upside
High target
$10
78%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Wells Fargo
Tiago Fauth
57% 1-year accuracy
13 / 23 met price target
60%upside
$9
Overweight
Initiated
20 Dec 2024
RBC Capital
Gregory Renza
36% 1-year accuracy
20 / 55 met price target
78%upside
$10
Outperform
Upgraded
19 Dec 2024

Financial journalist opinion

Neutral
Seeking Alpha
6 days ago
MoneyShow's Best Investment Ideas For 2025: Part 8
MoneyShow presents top investment ideas for 2025 from their contributors. This year's edition presents a broad mix of theme-based stock picks, momentum-driven high-flyers and beaten-up stocks with turnaround potential, along with some speculative plays and ETFs. Part 8 includes American Superconductor, Skye Bioscience, Healwell AI, Dell Technologies, MicroStrategy and MannKind, among others.
MoneyShow's Best Investment Ideas For 2025: Part 8
Neutral
GlobeNewsWire
1 month ago
MannKind Expands Executive Leadership Team
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focusing on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Dominic Marasco, RPh, has joined the company as President, Endocrine Business Unit, effective January 6, 2025.
MannKind Expands Executive Leadership Team
Neutral
Seeking Alpha
1 month ago
MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets
MannKind Corporation is a biopharmaceutical company focused on inhaled therapies for endocrine and orphan lung diseases. MNKD's revenue growth is driven by Tyvaso DPI royalties and Afrezza expansion, with pediatric trials targeting a significant underserved market. MNKD's pipeline includes MNKD-101 for nontuberculous mycobacterial lung disease and MNKD-201 for idiopathic pulmonary fibrosis, with significant market potential if successfully commercialized.
MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets
Neutral
GlobeNewsWire
1 month ago
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
Company plans to meet with FDA regarding potential sNDA submission in 1H 2025 Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression DANBURY, Conn.
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
Neutral
GlobeNewsWire
1 month ago
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
India has the 2 nd highest burden of diabetes worldwide CDSCO decision follows existing approvals in the U.S.A. and Brazil MannKind expects to ship product for Cipla Ltd.
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
Neutral
Seeking Alpha
3 months ago
MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript
MannKind Corporation (NASDAQ:MNKD ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Michael Castagna - CEO Chris Prentiss - CFO Conference Call Participants Andreas Argyrides - Oppenheimer Olivia Brayer - Cantor Fitzgerald Faisal Khurshid - Leerink Partners Anish Nikhanj - RBC Capital Markets Brandon Folkes - Rodman & Renshaw Operator Good afternoon, and welcome to the MannKind Corporation Third Quarter 2024 Financial Results Earnings Call. As a reminder, this call is being recorded on November 7th, 2024, and will be available on the MannKind Corporation website shortly after the conclusion of this call and available for approximately 90 days.
MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript
Positive
Zacks Investment Research
3 months ago
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say
Positive
Zacks Investment Research
3 months ago
MannKind (MNKD) Matches Q3 Earnings Estimates
MannKind (MNKD) came out with quarterly earnings of $0.04 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.02 per share a year ago.
MannKind (MNKD) Matches Q3 Earnings Estimates
Neutral
GlobeNewsWire
3 months ago
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
Conference Call to Begin Today at 4:30 p.m. (ET) 3Q 2024 Total revenues of $70M; +37% vs.
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update
Neutral
GlobeNewsWire
3 months ago
MannKind to Present at 2024 UBS Healthcare Conference
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
MannKind to Present at 2024 UBS Healthcare Conference
Charts implemented using Lightweight Charts™